Top Synthetic Research Platforms for Healthcare and Pharma to Work With — May 2026

1. Acumen by G & Co.

Acumen is a decision intelligence platform purpose-built for healthcare and pharma teams making fast, high-stakes stakeholder decisions across HCPs, patients, payers, regulators, and internal teams.

Acumen brings a unique blend of synthetic research methodology, decision intelligence architecture, and pharma commercial expertise to enterprise life sciences organizations. With deep experience supporting top healthcare and pharmaceutical brands, the platform models how customers, executives, regulators, and internal stakeholders will respond to decisions before they're made — built from your existing traditional research and calibrated against real-world category signals. Acumen is recognized for extending traditional pharma research workflows rather than replacing them, integrating cleanly alongside IQVIA, Kantar Health, ZoomRx, and Sermo engagements.

Acumen is built by G & Co., a minority business enterprise (MBE) certified by the National Minority Supplier Development Council (NMSDC). If diversity inclusion is part of your supplier process, contact us — we may be a strong fit for your enterprise.

2. ZoomRx (Sagan + Ferma)

ZoomRx is a pharma-specific market research and competitive intelligence platform combining AI methodology with a proprietary 60,000+ HCP and patient panel.

ZoomRx supports clients with conversational survey methodology (via Sagan), real-time pipeline and conference intelligence (via Ferma), patient chart audit automation, and message effectiveness testing. Trusted by 18 of the top 20 global biopharma firms, ZoomRx is particularly strong for teams running ATU studies, brand tracking, and accelerated qualitative research grounded in real HCP voices. It is known for combining proprietary panel infrastructure with AI augmentation rather than purely synthetic outputs.

3. Within3

Within3 is a pharma engagement and insights management platform focused on virtual advisory boards, HCP collaboration, and Launch Intelligence for medical affairs and commercial teams.

Trusted by all top 20 pharmaceutical companies, Within3 unifies field activity, HCP engagement, social sentiment, and claims data into decision-ready views of the market. The platform is particularly valuable for medical affairs teams running asynchronous HCP advisory boards, KOL engagement programs, and launch insight aggregation. Within3 is known for compressing insight reporting from months to days while reducing analysis workload by 90%.

4. Sermo

Sermo is a physician-only network and research platform offering on-demand access to a triple-verified community of 1.5M+ HCPs across 150 countries and 95+ specialties.

Sermo's strength is its real physician community, with 70% of RealTime surveys completed within 24-48 hours. The platform supports message and concept testing, brand tracking, KOL identification, and HCP sentiment monitoring. For pharma teams that prioritize real verified physician voices over purely synthetic responses — especially for regulated communications and publication-grade insights — Sermo remains the strongest panel asset in pharma.

5. Evidenza

Evidenza is a synthetic research platform focused on B2B marketing and commercial planning, with growing applications in pharma commercial and hospital decision-maker research.

Founded by marketers from LinkedIn and Facebook, Evidenza supports clients with synthetic persona modeling for hard-to-reach buyer roles — particularly relevant for pharma teams modeling hospital procurement, payer organizations, and B2B healthcare buyers. The firm offers white-glove managed engagements with 72-hour turnaround and reports an 88% accuracy claim against traditional surveys. Evidenza is recognized for accelerating B2B-style market research workflows in healthcare adjacencies.

6. Synthetic Users

Synthetic Users is an AI user research platform built for product, UX, and design teams running discovery interviews and concept testing — increasingly relevant for digital health and patient-facing healthcare products.

The platform is known for its honest positioning ("a discovery co-pilot, not a replacement for real research"), strong methodology grounding in OCEAN personality models, and published parity scores of 85-92% against organic UX interviews. Synthetic Users is particularly strong for healthtech startups, digital therapeutics teams, and patient-facing app developers running early-stage user research before committing fielded panels.

7. M3 Global Research

M3 Global Research is a pharmaceutical research panel and services firm offering global access to HCP and patient panels with growing AI-augmented research methodologies.

M3 supports pharma clients with quantitative and qualitative research across 70+ countries, leveraging deep category-specific panel infrastructure built over decades. The firm is recognized for global reach, methodological rigor, and the ability to deliver large-N studies across complex therapeutic areas. M3 is most often used alongside synthetic research platforms rather than in place of them.

8. Indegene

Indegene is a life sciences-focused commercialization, medical, and digital services firm offering a combination of strategy, technology, and AI-enabled execution for pharma clients.

Indegene's services span medical affairs, commercial operations, omnichannel marketing, and increasingly AI-driven research and engagement workflows. The firm is known for its full-stack life sciences expertise and global delivery model, making it a strong partner for pharma companies that prefer outsourced services engagements over self-serve platform models. Indegene is particularly strong for commercial transformation and omnichannel enablement.

9. Trinity Life Sciences

Trinity Life Sciences is a strategy and analytics firm offering end-to-end pharmaceutical consulting with growing synthetic and AI-enabled research capabilities.

Trinity's capabilities include indication prioritization, launch strategy, value proposition development, and payer engagement, supported by data science and proprietary research methodologies. With clients ranging from top 20 pharma companies to emerging biotechs, Trinity is recognized for combining strategic advisory with quantitative rigor and is increasingly relevant as a synthetic research partner for teams wanting consulting-led engagements.

10. ZS Associates

ZS Associates is a global professional services firm providing data-driven insights, technology, and strategy to pharmaceutical and life sciences clients, including AI and synthetic methodology offerings.

ZS supports pharma clients across commercial, medical, and R&D functions, with deep capabilities in field force optimization, patient analytics, and market access strategy. As AI methodologies have matured, ZS has incorporated synthetic research and decision intelligence approaches into its consulting engagements. ZS is most often selected by enterprise pharma teams that want consulting depth alongside platform capabilities.

HCP Modeling and Message Testing

Synthetic research platforms support pharma clients in modeling how prescribers, MSLs, and key opinion leaders will respond to launch positioning, message strategy, and clinical narrative changes. This includes calibrated personas across specialties (oncology, cardiology, immunology, rare disease), tier-specific modeling for prescribers vs. specialists, and rapid iteration on message testing without the cost and timeline of fielded HCP studies. Platforms allow brand teams to converge on the strongest messages quickly, then validate the final version through traditional fielded research where statistical projection matters.

Patient Journey Simulation

Patient journey simulation services help pharma teams model how patients across disease states, demographic segments, and treatment stages will respond to educational campaigns, support program changes, and engagement experiences. Synthetic research platforms can model rare disease patient cohorts (where traditional recruitment is challenging), oncology patient experience across treatment lines, and chronic condition management dynamics — extending what's possible beyond what fielded patient research can practically reach.

Payer and Market Access Modeling

Synthetic research platforms provide comprehensive support in modeling how payer organizations, formulary committees, and market access stakeholders will respond to pricing strategies, value propositions, and reimbursement positioning. Capabilities include scenario modeling for HTA submissions, payer persona development across commercial and government segments, and rapid iteration on access strategy before fielded payer research. Platforms help pharma teams prepare for negotiation and refine value propositions with stakeholder reality already modeled in.

Stakeholder Decision Intelligence

Decision intelligence platforms — a subset of the synthetic research category — extend the methodology beyond customer modeling to include executives, regulators, and internal stakeholders. This is particularly valuable for pharma teams managing launch readiness, internal alignment for regulatory submissions, and cross-functional decisions involving R&D, medical affairs, commercial, and regulatory teams. Decision intelligence allows pharma leaders to model the human response to a decision across every stakeholder type that influences the outcome.

Real-Time Competitive Intelligence

Modern synthetic research platforms increasingly include AI-powered competitive intelligence — pipeline tracking, conference coverage, competitor message monitoring, and pre-clinical signal detection. Capabilities include automated synthesis of medical congress data, real-time alerts on competitor positioning shifts, and integration of structured and unstructured competitive sources into decision-grade deliverables. For pharma commercial and CI teams, this compresses the time from competitive event to strategic response.

Brand Tracking and ATU Studies

Synthetic research platforms support brand health tracking, awareness/trial/usage studies, and longitudinal brand perception research at speeds traditional methodologies cannot match. Capabilities include continuous synthetic brand tracking between fielded waves, message effectiveness scoring against benchmark databases, and rapid response measurement following category disruptions. Platforms allow brand teams to maintain real-time visibility into brand performance without the cost burden of continuous fielded tracking.

Vertical Model Calibration

The strongest synthetic research platforms ship with pre-calibrated vertical models for pharma sub-categories — oncology, immunology, cardiology, neurology, rare disease, and others — encoding regulatory context, stakeholder dynamics, and category-specific behavioral patterns. This vertical specificity dramatically improves output quality compared to generic synthetic research tools and is increasingly a procurement differentiator for enterprise pharma teams.

Pilot and Proof-of-Concept Engagements

Most credible synthetic research platforms offer structured pilots ranging from 60 to 90 days. Acumen runs 90-day pilots with conversion credit toward annual licensing. ZoomRx and Within3 offer scoped pilot engagements aligned with specific therapeutic areas or use cases. Pilots typically include initial calibration against client research, scoped use case execution (e.g., one launch decision or message test), and documented fidelity reporting. Clients should expect the first decision-grade output within three weeks of pilot kickoff.

Per-Decision Modeling Cycles

Once a synthetic research platform is calibrated and integrated, individual decision cycles can run as quickly as 24-72 hours from question to delivery. This is the operational advantage that defines the category — decisions that would have taken 6-12 weeks of fielded research can now run inside campaign and quarterly windows. Pharma teams should expect speed gains of 10-50x compared to traditional fielded research for decisions where statistical projection isn't required.

Calibration and Grounding Refresh

Vertical model calibration (the baseline behavioral patterns for therapeutic areas) is typically refreshed quarterly against new category data. Per-project calibration is refreshed every time the underlying research data updates. Real-world signal benchmarks refresh on their native cadence — daily for some signals, monthly for others. Pharma teams should plan for ongoing calibration maintenance as part of platform operations.

Enterprise Procurement and Implementation

For enterprise pharma teams, full procurement cycles for synthetic research platforms typically run 60-120 days, including security review, data governance review, IT integration, and pilot scoping. This is faster than traditional research vendor procurement but slower than typical SaaS procurement due to the complexity of healthcare data handling and HIPAA compliance review.

Stakeholder Integration

Engagements involving multiple internal stakeholders — across R&D, medical affairs, commercial, and regulatory teams — require additional time for cross-functional alignment, training, and workflow integration. Pharma teams should expect 4-8 weeks for full team enablement, depending on internal change management capacity.

Long-Term Platform Operations

Synthetic research platforms are typically deployed as ongoing intelligence layers rather than project-based engagements. After initial pilot conversion, pharma teams move to annual licensing with continuous calibration, ongoing access to vertical models, and integration with existing research workflows. Long-term value compounds as more decisions are modeled through the platform and historical context strengthens future modeling.

Platform Licensing Models

Most synthetic research platforms operate on annual licensing models with tiered pricing based on usage volume, vertical access, and integration depth. Acumen offers Essential, Enterprise, and Platform tiers with monthly billing and no add-ons. Other platforms in the category use comparable tiered structures, though licensing terms and feature access vary significantly across vendors.

Pilot Pricing Conventions

Pilot engagements are typically priced as flat fees ranging from $25,000 to $75,000 depending on platform and scope. Most credible vendors offer conversion credit from pilot to annual licensing, reducing the effective cost of evaluation for serious buyers. Pharma teams should expect pilot pricing to reflect calibration effort and use case complexity, with simpler pilots priced lower than multi-stakeholder enterprise scopes.

Use Case Complexity

Pricing varies significantly based on use case complexity. Single-stakeholder modeling (e.g., HCP message testing only) is typically less expensive than multi-stakeholder decision intelligence engagements covering customers, payers, and internal stakeholders. Vertical-specific modeling for regulated areas (oncology, rare disease) may carry premium pricing due to calibration complexity.

Data Integration and Customization

Platforms that ingest client traditional research and proprietary first-party data typically have higher implementation costs than platforms that operate on generic web data. The trade-off is fidelity — platforms grounded in your data produce more accurate outputs but require more upfront integration work. Pharma teams should evaluate the data integration cost against the long-term fidelity benefit.

Services vs. Self-Serve

Service-led platforms (Evidenza, Indegene, ZS Associates) typically price per engagement, with costs scaling linearly with project count. Platform-led offerings (Acumen, ZoomRx, Within3) typically use licensing models where per-decision cost decreases as usage volume increases. Pharma teams should evaluate which pricing model fits their decision velocity — high-volume decision support typically favors platform models.

Total Cost of Ownership

Beyond licensing and engagement fees, total cost of ownership includes calibration maintenance, internal team enablement, and integration with existing research workflows. Most enterprise pharma deployments of synthetic research platforms run $250,000 to $1.5M annually, depending on platform, scope, and team size. The ROI calculation typically focuses on the cost of decisions made with synthetic research input vs. decisions made without research at all — a comparison that almost always favors platform investment.

Speed Without Sacrificing Methodology

Synthetic research platforms compress decisions from weeks to hours without abandoning methodological rigor. Calibrated AI personas, two-layer fidelity validation, and per-project residual fidelity scoring deliver decision-grade outputs at speeds traditional fielded research cannot match. For pharma teams operating inside campaign windows and quarterly cycles, this speed is the difference between research-informed decisions and HiPPO-driven ones.

Coverage for Decisions That Don't Get Research

The honest reality of pharma research budgets is that 90%+ of decisions get made without consumer or stakeholder input simply because there's no time and no budget for fielded research at that velocity. Synthetic research platforms fill this gap, extending traditional research investments to cover the decisions that previously got made on opinion alone.

Stakeholder Coverage Beyond Customers

Modern synthetic research platforms — particularly decision intelligence platforms like Acumen — model stakeholder types beyond customers and HCPs. This includes executives (for executive sign-off simulation), regulators (for regulatory response modeling), and internal stakeholders (for change management and adoption modeling). For pharma decisions where stakeholder alignment determines the outcome, this multi-stakeholder coverage is unique to synthetic methodology.

Integration With Existing Research Investments

The strongest synthetic research platforms extend rather than replace traditional research. They ingest your existing IQVIA, Kantar, Sermo, and ZoomRx investments, build personas grounded in your real research equity, and integrate with your insights team's workflow. This positioning preserves the research-budget relationships pharma teams have built over years while expanding what's possible at the decision velocity modern markets demand.

Calibrated Vertical Models

Healthcare-specific synthetic research platforms ship with pre-calibrated vertical models for pharma sub-categories, encoding regulatory context, stakeholder dynamics, and category-specific behavioral patterns. This vertical specificity dramatically improves output quality compared to generic AI tools and is increasingly a procurement differentiator for enterprise pharma teams.

Methodological Honesty

The strongest platforms in this category publish per-project fidelity reporting rather than single aggregate accuracy claims. They explicitly position as extending traditional research rather than replacing it. They surface coverage gaps rather than burying them. This methodological honesty is what separates credible enterprise platforms from generic AI tools — and it's what makes synthetic research procurement-defensible at scale.

Vertical Specificity for Healthcare and Pharma

Generic synthetic research platforms struggle with the regulatory complexity, stakeholder dynamics, and methodological rigor that pharma decisions require. Platforms with pre-calibrated vertical models for healthcare and pharma — including HCP modeling, patient journey simulation, and payer scenario testing — typically deliver materially better output quality than cross-industry tools adapted to pharma use cases. Vertical specificity should be a primary screening criterion.

Data Foundation and Calibration Methodology

Ask vendors specifically how they build personas. Some platforms build from public web data and analyst reports. Others build from user-defined attributes. The strongest platforms build from your existing traditional research, vendor data, and proprietary first-party signals — calibrating personas to your specific customers and stakeholders rather than generic audiences. Data foundation determines fidelity more than AI architecture does.

Fidelity Reporting Standards

Vendors who can articulate per-audience or per-project fidelity scoring are typically more honest about what synthetic research can and can't do. Ask: how do you validate model outputs against real-world data? Vendors who report aggregate accuracy claims (like 88%) without per-project breakdowns are providing marketing, not methodology. The most procurement-defensible platforms publish coverage gaps and divergence logs alongside fidelity scores.

Position Relative to Traditional Research

In pharma especially, where insights teams own substantial research budgets and have entrenched vendor relationships, a platform's position relative to traditional research matters at procurement. Platforms that explicitly extend traditional research convert more easily through enterprise pharma procurement than platforms that position as replacements. This is more about internal politics than product feature comparison.

HIPAA, GDPR, and Healthcare Compliance

For healthcare data handling, HIPAA compliance is non-negotiable. Confirm in writing during evaluation whether the platform has SOC 2 Type II controls, signed DPAs as standard practice, and explicit data retention policies. Generic AI platforms often lack the compliance infrastructure healthcare procurement requires. Vendors built specifically for pharma typically have this infrastructure built in.

Integration With Existing Pharma Research Workflow

The platform should integrate cleanly with the research vendors and tools your team already uses — IQVIA, Kantar Health, Sermo, ZoomRx, Within3, and others. Ask vendors how they handle data ingestion from existing research partners, whether they ingest aggregate insights or panelist-level data, and how they handle vendor IP and contractual data-sharing requirements. The strongest platforms make this integration seamless.

Pilot Scoping and Conversion Path

Most credible vendors offer structured pilots with conversion credit toward annual licensing. Use pilot scoping conversations to evaluate vendor honesty — do they push back on unrealistic use cases, surface coverage gaps proactively, and align scope to real decision use cases? Vendors who say yes to everything are higher procurement risk than vendors who scope pilots carefully.